cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Oramed Pharmaceuticals Inc
5 own
12 watching
Current Price
$1.94
$0.01
(0.52%)
logo-ormp
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
75.88M
52-Week High
52-Week High
13.73
52-Week Low
52-Week Low
1.81
Average Volume
Average Volume
1.58M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization75.88M
icon52-Week High13.73
icon52-Week Low1.81
iconAverage Volume1.58M
iconDividend Yield--
iconP/E Ratio--
What does the Oramed Pharmaceuticals Inc do?
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Read More
How much money does Oramed Pharmaceuticals Inc make?
News & Events about Oramed Pharmaceuticals Inc.
PR Newswire
18days ago
Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes PR Newswire NEW YORK, Jan. 11, 2023 NEW YORK, Jan. 11, 2023 /PRNewswire/ -- Oramed...
PR Newswire
26days ago
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes PR Newswire NEW YORK, Jan. 4, 2023 NEW YORK, Jan. 4, 2023 /PRNewswire/ --Oramed...
PR Newswire
1month ago
Oramed Letter to Shareholders Oramed Letter to Shareholders PR Newswire NEW YORK, Dec. 21, 2022 Topline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023Phase 2 NASH Trial Achieved Primary and Secondary EndpointsDefinitive Deal Signed to Commercialize Oral Insulin in South Korea $160...
PR Newswire
2 months ago
Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH PR Newswire NEW YORK, Nov. 17, 2022 Achieved primary endpoint of...
PR Newswire
3 months ago
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine PR Newswire NEW YORK, Oct. 7, 2022 Primary and secondary endpoints of safety and immunogenicity met Oral...
Frequently Asked Questions
Frequently Asked Questions
What is Oramed Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Oramed Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Oramed Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Oramed Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Oramed Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Oramed Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Oramed Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Oramed Pharmaceuticals Inc?
plus_minus_icon
What percentage is Oramed Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Oramed Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.94
$0.01
(0.52%)
logo-ormp
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
VBI Vaccines Inc
VBI Vaccines Inc
$0.60
$0.02 (4.00 %)
RETRACTABLE TECHNOLOGIES INC
RETRACTABLE TECHNOLOGIES INC
$1.96
$0.01 (0.51 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$2.09
$-0.02 (-0.95 %)
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
$1.70
$0.03 (1.80 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
VBI Vaccines Inc
VBI Vaccines Inc
$0.60
$0.02 (4.00 %)
RETRACTABLE TECHNOLOGIES INC
RETRACTABLE TECHNOLOGIES INC
$1.96
$0.01 (0.51 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$2.09
$-0.02 (-0.95 %)
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
$1.70
$0.03 (1.80 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00